Abstract
The aim of this study was to evaluate the expression of TIM-3 in renal tissue from patients with systemic lupus erythematosus (SLE) and patients without SLE, and to evaluate the difference of TIM-3 expression between them. A total of 272 patients with SLE as SLE group and 62 patients without SLE as control group were enrolled in the present study. Patients with SLE accepted percutaneous renal biopsy. We examined the expression of TIM-3 in renal tissue and the serological parameters in serum from all enrolled cases. The expression of TIM-3 and serological parameters were compared between the different groups. Positive staining of TIM-3 protein was seen in 97.1 % patients with SLE (264 out of 272), but 95.2 % negative staining in the cases without SLE (59 out of 62), only 3 out of 62 patients in control group were positive staining of TIM-3. There were significant differences between two groups in almost all serological markers which reflect SLE activity. There was a nearly positive correlation between pathological manifestations and expression degree of TIM-3. High immuno-reactivity of TIM-3 was found to be significantly correlated with serological grade (p < 0.001), but there was the phenomenon in control group. The results showed that there was the expression of TIM-3 in renal tissue from the patients with SLE, but rarely expression in cases without SLE. Expression of TIM-3 was associated with the diseases’ activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, Magder LS et al (2002) Expression of cytokine-and chemokine-related genes in peripheral blood mononuclear cells from Lupus patients by cDNA array. Clin Immunol 102:283–290
Rus V, Atamas SP, Shustova V (2003) Pathogenesis of systemic lupus erythematosus. Clin Pathol 56:481–490
Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T et al (2002) Th1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536–541
Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW et al (2010) T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology 139(6):2195–2206
Pan HF, Zhang N, Li WX, Tao JH, Ye DQ (2010) TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep 37(1):395–398
Li X, Zhao YQ, Li CW, Yuan FL (2012) T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis. Expert Opin Ther Targets 16(12):1145–1149
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521–530
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
Li Z, Ju Z, Frieri M (2013) The T-cell immunoglobulin and mucin domain (TIM) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc 34(1):e21–e26
Wang Y, Liu ZL, Sun J, Ilham I, Hu HF, Zhang H (2011) Relationship between polymorphism sites of TIM-3 and allergic rhinitis in a population of Uigurs and Hans from Xinjiang Uigur Autonomous Region of China. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 46(9):712–717
Li WX, Chen GM, Yuan H, Yao YS, Li RJ, Pan HF et al (2011) Polymorphisms of the TIM-1 and TIM-3 genes are not associated with systemic lupus erythematosus in a Chinese population. Mutagenesis 26(4):507–511
Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L et al (2013) TIM-3 expression in cervical cancer promotes tumor metastasis. PLoS One 8(1):e53834
Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K et al (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127(1):78–88
Du WT, Zhao HF, Xu JH, Gu DS, Xue F, Ge J et al (2009) The role of T-cell immunoglobulin- and mucin-domain-containing molecule-3 polymorphisms in idiopathic thrombocytopenic purpura. Hum Immunol 70(6):398–402
Chae SC, Park YR, Shim SC, Yoon KS, Chung HT (2004) The polymorphisms of Th1 cell surface gene TIM-3 are associated in a Korean population with rheumatoid arthritis. Immunol Lett 95(1):91–95
Pan HF, Ye DQ, Li XP (2008) Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4(7):352–353
Niwa H, Satoh T, Matsushima Y, Hosoya K, Saeki K, Niki T et al (2009) Stable form of galectin-9, a TIM-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clin Immunol 132(2):184–194
Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L et al (2008) Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol 67(1):63–70
Acknowledgments
This study was supported by Shandong Province Family Planning Commission Research Fund, No. 2009-11 and No. 2010-11, Shandong Province Outstanding Young Scientist Research Award Fund Project, No. BS2010YY029, No. BS2013YY042. The authors express their appreciation to the enrolled patients.
Conflict of interest
None declared.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ling Guo and Xiangdong Yang have contributed equally to this work and should be considered co-first authors.
Tao Peng and Xuewei Zhuang have contributed equally to this work and should be considered co-corresponding authors.
Rights and permissions
About this article
Cite this article
Guo, L., Yang, X., Xia, Q. et al. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients. Clin Exp Med 14, 383–388 (2014). https://doi.org/10.1007/s10238-013-0264-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-013-0264-3